SSY GROUP (02005.HK): Nimodipine oral solution wins production nod

NewTimeSpace News: On 8 October 2026, SSY Group Limited (stock code: 02005.HK) announced that the Group has obtained a drug production registration approval from China's National Medical Products Administration for nimodipine oral solution (10ml:60mg), classified as a Category 3 chemical drug and deemed to have passed consistency evaluation.

Nimodipine oral solution is mainly used in adult patients with subarachnoid haemorrhage (SAH) from ruptured intracranial saccular aneurysms, improving neurological outcomes by reducing the incidence and severity of ischaemic neurological injury. The Group's nimodipine API was registered for use in marketed formulations on 19 March 2025, and the approval of the oral solution achieves API-formulation integration and further enriches the Group's product portfolio in the cardiovascular, cerebrovascular and neurocritical care areas.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.